Ensartinib is a targeted therapy drug designed to target specific gene mutations, and it is mainly indicated for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) confirmed to be anaplastic lymphoma kinase (ALK)-positive through testing. Its indications cover treatment-naive patients or those who have experienced disease progression after receiving other ALK inhibitors, and it may provide clinical benefits for patients with brain metastases under specific circumstances.
Specific Populations Indicated for Use
1. ALK-Positive Non-Small Cell Lung Cancer Patients
Confirmation of ALK gene fusion mutation through genetic testing (e.g., fluorescence in situ hybridization [FISH], polymerase chain reaction [PCR] or next-generation sequencing [NGS]) is a prerequisite for the administration of ensartinib.
It is indicated for cases of unresectable locally advanced disease or metastatic disease, especially when conventional chemotherapy or immunotherapy has shown suboptimal efficacy.
2. First-Line or Subsequent Treatment Option
Treatment-naive patients: It can be used as a first-line therapy option to inhibit tumor growth and prolong progression-free survival.
Patients with drug resistance: If drug resistance or disease progression occurs after previous treatment with ALK inhibitors such as crizotinib, ensartinib can be used as a subsequent treatment regimen.
3. Patients with Brain Metastases
Ensartinib can cross the blood-brain barrier and exert a certain control effect on brain lesions, making it suitable for ALK-positive patients accompanied by brain metastases.
Precautions for Use
1.Adverse Effect Management
Common adverse reactions include rash, fatigue, and abnormal liver function. Regular monitoring is required, and medication should be adjusted based on symptoms.
2.Drug Interactions
Avoid concomitant use with potent CYP3A inducers (e.g., rifampicin) or inhibitors (e.g., ketoconazole), as this may affect drug efficacy or increase toxicity.
3.Special Populations
Patients with impaired hepatic or renal function, or those who are pregnant or lactating, need to undergo careful risk assessment and strictly follow the doctor's instructions for medication.
Principles of Medication Use
Ensartinib is a prescription drug and must be used under the guidance of an oncologist. The treatment plan should be formulated comprehensively based on the patient's genetic testing results, disease stage, and overall health status. During the treatment period, regular re-examinations are required to evaluate efficacy and safety. In case of severe adverse reactions or changes in the patient's condition, medical attention should be sought promptly to adjust the treatment strategy.
